Sirion Therapeutics Receives NDA Acceptance And Priority Review From The FDA For Durezol(TM) In The Treatment Of Postoperative Ocular Inflammation

Sirion Therapeutics, Inc., a privately held ophthalmic-focused biopharmaceutical company, announced that its New Drug Application (NDA) for Durezol(TM) has been accepted by the U.S. Food and Drug Administration (FDA) and granted priority review. Sirion Therapeutics is seeking approval from the FDA for its investigational compound Durezol(TM) (difluprednate ophthalmic emulsion) 0.05%, a twice-daily steroid, as a treatment for postoperative ocular inflammation.

More: continued here

Filed under: Eye Health on March 3rd, 2008